Latest Pharma Insights
ASH: Early Results Ready Lupeng’s Rocbrutinib For Potential Head-To-Head With Jaypirca
Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.
Scrip - December 12, 2025
Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.
Scrip - December 12, 2025
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - December 12, 2025
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - December 12, 2025
Slow Burn For US Sunscreen Innovation While FDA Lights Lamp For Monograph Overhaul Deadlines
Sunscreen products industry and public health advocacy groups have been critical that FDA has not approved a new filter since 1999 even as countries in Europe and other regions allow using numerous additional ingredients in sunscreens.
HBW Insight - December 12, 2025
Sunscreen products industry and public health advocacy groups have been critical that FDA has not approved a new filter since 1999 even as countries in Europe and other regions allow using numerous additional ingredients in sunscreens.
HBW Insight - December 12, 2025
US Sunscreen And OTC Monograph Milestones Marked By DSM-Firmenich’s Bemotrizinol Proposal
FDA’s proposed order follows its review of OMOR DSM-Firmenich submitted showing bemotrizinol, at concentrations up to 6%, is generally recognized as safe and effective and can be added as an active ingredient to sunscreen monograph.
HBW Insight - December 12, 2025
FDA’s proposed order follows its review of OMOR DSM-Firmenich submitted showing bemotrizinol, at concentrations up to 6%, is generally recognized as safe and effective and can be added as an active ingredient to sunscreen monograph.
HBW Insight - December 12, 2025
ASH: Early Results Ready Lupeng’s Rocbrutinib For Potential Head-To-Head With Jaypirca
Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.
Scrip - December 12, 2025
Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.
Scrip - December 12, 2025
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - December 12, 2025
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - December 12, 2025
Subsense Raises $10M To Advance Nanoparticle-Based Brain-Computer Interface Approach
Neurotech start-up Subsense raised another $10m, bringing its total seed funding to $27m. The proceeds will be used primarily to accelerate and enhance the company’s pre-clinical research program.
Medtech Insight - December 11, 2025
Neurotech start-up Subsense raised another $10m, bringing its total seed funding to $27m. The proceeds will be used primarily to accelerate and enhance the company’s pre-clinical research program.
Medtech Insight - December 11, 2025
Flow Wins FDA Approval For Depression Treatment Device
The US FDA has approved Flow Neuroscience’s at-home brain stimulation device for the treatment of depression, ending a frustrating wait for the Swedish firm.
Medtech Insight - December 11, 2025
The US FDA has approved Flow Neuroscience’s at-home brain stimulation device for the treatment of depression, ending a frustrating wait for the Swedish firm.
Medtech Insight - December 11, 2025
FDA Advisory Panel Says ‘Human Factor’ Essential In Evaluating Germicidal Ultraviolet Devices
The US FDA’s General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee convened Wednesday to discuss germicidal ultraviolet (GUV) devices as a mode of disinfection, a technology that has emerged since the COVID-19 pandemic.
Medtech Insight - December 11, 2025
The US FDA’s General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee convened Wednesday to discuss germicidal ultraviolet (GUV) devices as a mode of disinfection, a technology that has emerged since the COVID-19 pandemic.
Medtech Insight - December 11, 2025
Execs On The Move: December 1–5, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 11, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 11, 2025
Latest Regulatory Updates From The EU As Change Is In The Air
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Medtech Insight - December 11, 2025
Aerogen’s Vibrating Nebulizer Could Be Breakthrough For Premature Infants
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes
Medtech Insight - December 11, 2025
Slow Burn For US Sunscreen Innovation While FDA Lights Lamp For Monograph Overhaul Deadlines
Sunscreen products industry and public health advocacy groups have been critical that FDA has not approved a new filter since 1999 even as countries in Europe and other regions allow using numerous additional ingredients in sunscreens.
HBW Insight - December 12, 2025
Sunscreen products industry and public health advocacy groups have been critical that FDA has not approved a new filter since 1999 even as countries in Europe and other regions allow using numerous additional ingredients in sunscreens.
HBW Insight - December 12, 2025
US Sunscreen And OTC Monograph Milestones Marked By DSM-Firmenich’s Bemotrizinol Proposal
FDA’s proposed order follows its review of OMOR DSM-Firmenich submitted showing bemotrizinol, at concentrations up to 6%, is generally recognized as safe and effective and can be added as an active ingredient to sunscreen monograph.
HBW Insight - December 12, 2025
FDA’s proposed order follows its review of OMOR DSM-Firmenich submitted showing bemotrizinol, at concentrations up to 6%, is generally recognized as safe and effective and can be added as an active ingredient to sunscreen monograph.
HBW Insight - December 12, 2025
Cipla Launches Second Tirzepatide As Wegovy Price Cuts Tighten Gap With Mounjaro
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Cipla’s rollout of Lilly’s tirzepatide second brand comes as Wegovy price cuts tighten competition in India’s fast-growing GLP-1 market.
Generics Bulletin - December 11, 2025
Council And Parliament Reach Deal On EU Pharma Legislation Reform
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
Responding to the newly-agreed EU pharma package, Medicines for Europe said the deal was a limited political compromise that could have been more ambitious – particularly when it comes to access – but nevertheless represented “an important step forward” and “progress” for the EU pharma sector.
Generics Bulletin - December 11, 2025
US Government Fights Hikma’s Corner In Skinny Label Vascepa Row
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
“Section viii cannot function as Congress intended,” if a Federal Circuit ruling stands, the US solicitor general has argued as he urged the Supreme Court to review and reverse the closely-watched Hikma skinny-label Vascepa case.
Generics Bulletin - December 11, 2025
German Giants Rise Up The Ranks In Generics Bulletin’s Top 50
Two leading German generics and biosimilars giants are the big movers at the top of our annual ranking of off-patent industry leaders. We reveal the latest developments in this year’s Generics Bulletin Top 50.
In Vivo - December 10, 2025
Two leading German generics and biosimilars giants are the big movers at the top of our annual ranking of off-patent industry leaders. We reveal the latest developments in this year’s Generics Bulletin Top 50.
In Vivo - December 10, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
In Vivo - December 10, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
In Vivo - December 10, 2025
Execs On The Move: November 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - December 10, 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - December 10, 2025
Indegene Exec On R&D Operations In The Age Of GenAI, One Click Submissions
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In Vivo - December 10, 2025
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In Vivo - December 10, 2025
Podcast: Kairos Pharma’s Approach To Resensitizing Tumors
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
In Vivo - December 10, 2025
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
In Vivo - December 10, 2025